DRUG NEWS: Inhaled antirejection drug shows promise

July 2004 
Volume 34  Number 7
Pages 26 - 27
  PDF Version Available!

© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(7)             July 2004             p 26–27 Inhaled antirejection drug shows promise [DRUG NEWS: LUNG TRANSPLANTS]

Lung transplant recipients who inhale an antirejection drug may increase their chances of survival fourfold, according to a new study. Patients undergoing this new, organ-specific approach to antirejection therapy inhale an experimental version of cyclosporine. Delivered directly to the lungs, the drug appears to stop immune cells from attacking vulnerable transplanted tissue.

In a study of 56 new lung recipients, half received the inhaled form of cyclosporine and half received a placebo inhalant. All patients used their inhalant 3 days a week for 2 years following their transplant. Patients in both groups also received standard antirejection therapy.

Researchers followed patients for 2 to 5 years after their transplant. ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

Featured Jobs

Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member